RxDoctor Payments Data

Leo Odle, DO

Internal Medicine · Gilbert, AZNPI 1073601415

Payments from drug & device makers

$607in general payments, 2019–2025

Across 34 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$180
  • Boehringer Ingelheim$110
  • AbbVie$67
  • Novo Nordisk$46
  • Takeda Pharmaceuticals U.S.A., Inc.$45
  • AstraZeneca$41
  • plus $119 from 7 others

What the payments were for

  • Food & beverage$57695%
  • Education$315%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$607 in reported general payments places this provider in the 70th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$132,717
Medicare patients
338
Services billed
1,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$93,865
EliquisApixaban77$86,502
JardianceEmpagliflozin47$72,176
Tresiba Flextouch U-100Insulin Degludec13$31,011
MounjaroTirzepatide18$19,649
XareltoRivaroxaban11$14,473
RybelsusSemaglutide11$14,131
SymbicortBudesonide/Formoterol Fumarate14$8,009
PremarinEstrogens, Conjugated15$5,942
LantusInsulin Glargine,hum.Rec.Anlog12$5,092
Levothyroxine Sodium379$3,984
Rosuvastatin Calcium369$3,656
Gabapentin145$3,632
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$3,043
Atorvastatin Calcium351$3,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$46$107,99684 claims
PfizerEliquis, Premarin$11$92,44392 claims
Boehringer IngelheimJardiance$110$72,17647 claims
AstraZenecaSymbicort$41$8,00914 claims
Sanofi-aventis U.S. LLCLantus$12$5,09212 claims
AbbVieSynthroid$67$1,22434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →